

11/539,486

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 4 APR 04 STN AnaVist \$500 visualization usage credit offered
NEWS 5 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS 6 MAY 11 KOREAPAT updates resume
NEWS 7 MAY 19 Derwent World Patents Index to be reloaded and enhanced
NEWS 8 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAPLUS and
USPATFULL/USPAT2
NEWS 9 MAY 30 The F-Term thesaurus is now available in CA/CAPLUS
NEWS 10 JUN 02 The first reclassification of IPC codes now complete in
INPADOC
NEWS 11 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and
and display fields
NEWS 12 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 13 JUL 11 CHEMSAFE reloaded and enhanced
NEWS 14 JUL 14 FSTA enhanced with Japanese patents
NEWS 15 JUL 19 Coverage of Research Disclosure reinstated in DWPI
NEWS 16 AUG 09 INSPEC enhanced with 1898-1968 archive

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:34:44 ON 14 AUG 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION

11/539,486

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:34:55 ON 14 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 AUG 2006 HIGHEST RN 901009-82-3
DICTIONARY FILE UPDATES: 13 AUG 2006 HIGHEST RN 901009-82-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10539486.str



chain nodes :

6 7 21 22 23

ring nodes :

1 2 3 4 5 8 9 10 11 12 13 14 15 16 17 18 19

11/539,486

chain bonds :

2-7 4-8 5-6 7-21 11-14 21-22 22-23

ring bonds :

1-2 1-5 2-3 3-4 4-5 8-9 8-13 9-10 10-11 11-12 12-13 14-15 14-19 15-16
16-17 17-18 18-19

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 4-8 5-6 7-21 21-22 22-23

exact bonds :

2-7 11-14

normalized bonds :

8-9 8-13 9-10 10-11 11-12 12-13 14-15 14-19 15-16 16-17 17-18 18-19

isolated ring systems :

containing 8 :

G1:O,S

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
21:CLASS 22:CLASS 23:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 14:35:18 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 75 TO ITERATE

100.0% PROCESSED 75 ITERATIONS

16 ANSWERS

SEARCH TIME: 00.00.01

11/539,486


FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 981 TO 2019
PROJECTED ANSWERS: 80 TO 560

L2 16 SEA SSS SAM L1

=> d scan

L2 16 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Acetamide, N-[[(5S)-3-[4-[6-(1-aminocyclopropyl)-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI)
MF C20 H21 F N4 O3

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):15

L2 16 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-[4-(1-oxo-2-butenyl)-1-piperazinyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI)
MF C25 H28 F N5 O4

Absolute stereochemistry.
Double bond geometry unknown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 16 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Carbamic acid, [(1 α ,5 α ,6 β)-6-[5-[4-[(5S)-5-
 [(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,6-difluorophenyl]-2-
 pyridinyl]-3-oxabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI)
 MF C27 H30 F2 N4 O6

Absolute stereochemistry.


11/539,486



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 16 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-[4-(hydroxymethyl)-1H-imidazol-1-yl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)
MF C21 H20 F N5 O4

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 16 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Acetamide, N-[[(5S)-3-[3,5-difluoro-4-[6-[5-(4-oxazolyl)-2-furanyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)
MF C24 H18 F2 N4 O5

Absolute stereochemistry.


11/539,486



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 16 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Acetamide, N-[(5S)-3-[4-[6-(2,5-dihydro-1H-pyrrol-1-yl)-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)
MF C21 H21 F N4 O3

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 16 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Acetamide, N-[(5S)-3-[4-(6-amino-3-pyridinyl)-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)
MF C17 H16 F2 N4 O3

Absolute stereochemistry.


11/539,486



L2 16 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Cellulose, 2-hydroxypropyl methyl ether, compd. with N-[5-[4-[(5S)-5-
[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-2-
hydroxyacetamide (9CI)
MF C19 H19 F N4 O5 . x C3 H8 O2 . x C H4 O . x Unspecified

CM 1

Absolute stereochemistry.




CM 2

CM 3


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

11/539,486

CM 4




CM 5



L2 16 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Acetamide, N-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-2-hydroxy-, hydrochloride (9CI)
MF C19 H19 F N4 O5 . x Cl H


Absolute stereochemistry.



L2 16 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Carbamic acid, [(1 α ,5 α ,6 β)-6-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-3-oxabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI)
MF C27 H31 F N4 O6

Absolute stereochemistry.

11/539,486





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 16 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1-Piperazinecarboxylic acid, 4-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-, phenylmethyl ester (9CI)
MF C29 H30 F N5 O5

Absolute stereochemistry.

PAGE 1-A






PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 16 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Acetamide, N-[[[(5S)-3-[4-[6-[[bis(3-fluoropropyl)amino]methyl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)
 MF C24 H29 F3 N4 O3


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 16 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-, ethyl ester (9CI)
 MF C22 H21 F N6 O5


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 16 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Acetamide, N-[[[(5S)-3-[3,5-difluoro-4-[6-[4-[(E)-(methoxyimino)methyl]-1H-imidazol-1-yl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)
 MF C22 H20 F2 N6 O4


Absolute stereochemistry.
 Double bond geometry as shown.



L2 16 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(5-oxazolyl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)
 MF C20 H17 F N4 O4

Absolute stereochemistry.


11/539,486



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 16 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Acetamide, N-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]- (9CI)
MF C19 H19 F N4 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s 11 sss ful
FULL SEARCH INITIATED 14:35:41 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1450 TO ITERATE

100.0% PROCESSED 1450 ITERATIONS
SEARCH TIME: 00.00.01

301 ANSWERS

11/539,486

L3 301 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

167.38

167.59

FILE 'CAPLUS' ENTERED AT 14:35:49 ON 14 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Aug 2006 VOL 145 ISS 8

FILE LAST UPDATED: 13 Aug 2006 (20060813/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.

They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13

L4 45 L3

=> d 14 1-45 bib hitstr

L4 ANSWER 1 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:435301 CAPLUS

DN 145:39819

TI Effects of water deprivation for 72 hours on the pharmacokinetics of DA-7867, a new oxazolidinone, in rats

AU Bae, Soo K.; Kim, Yu C.; Lee, Jae K.; Kwon, Jong W.; Yoo, Moohi; Lee, Inchul; Lee, Myung G.

CS College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, S. Korea

SO Biopharmaceutics & Drug Disposition (2006), 27(3), 147-156

CODEN: BDDID8; ISSN: 0142-2782

PB John Wiley & Sons Ltd.

DT Journal

LA English

IT 380382-38-7, DA-7867


RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(DA-7867 pharmacokinetics in rat dehydration)

RN 380382-38-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:342903 CAPLUS
DN 144:390904
TI Phenyl-substituted oxazolidinone derivatives and their preparation,
pharmaceutical compositions, and use as antimicrobials
IN Das, Biswajit; Ahmed, Shahadat; Yadav, Ajay Singh; Ghosh, Soma; Gujrati,
Arti; Sharma, Pankaj; Rattan, Ashok
PA Ranbaxy Laboratories Limited, India
SO PCT Int. Appl., 145 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006038100	A1	20060413	WO 2005-IB2971	20051006
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI US 2004-616964P P 20041008

OS CASREACT 144:390904; MARPAT 144:390904

IT 883229-58-1P, N-[[[(5S)-3-[3,5-Difluoro-4-[6-(3-formyl-1H-pyrrol-1-yl)pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
883229-70-7P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of phenyl-substituted oxazolidinone derivs. as antimicrobials)

RN 883229-58-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3,5-difluoro-4-[6-(3-formyl-1H-pyrrol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

11/539,486


Absolute stereochemistry.



RN 883229-10-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3,5-difluoro-4-[6-(1H-1,2,4-triazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 883229-59-2P, N-[[[(5S)-3-[3,5-Difluoro-4-[6-[3-(hydroxymethyl)-1H-pyrrol-1-yl]pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide 883229-71-8P, N-[[[(5S)-3-[3,5-Difluoro-4-[6-[5-(1,3-oxazol-4-yl)-2-furyl]pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide 883229-72-9P, N-[[[(5S)-3-[3,5-Difluoro-4-[6-[5-(1,3-oxazol-4-yl)-2-thienyl]pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide 883229-73-0P, N-[[[(5S)-3-[3,5-Difluoro-4-[6-[3-[(E)-(hydroxyimino)methyl]-1H-pyrrol-1-yl]pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide 883229-76-3P, N-[[[(5S)-3-[3,5-Difluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide 883229-77-4P, N-[[[(5S)-3-[3,5-Difluoro-4-[6-(1H-imidazol-1-yl)pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide 883229-78-5P, N-[[[(5S)-3-[3,5-Difluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide 883229-82-1P, N-[[[(S)-3-[3,5-Difluoro-4-[6-(5-methyl-[1,3,4]oxadiazol-2-yl)pyridin-3-yl]phenyl]-2-oxooxazolidin-5-yl]methyl]acetamide 883229-83-2P, N-[[[(S)-3-[4-[6-(5-Amino-[1,3,4]thiadiazol-2-yl)pyridin-3-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-yl]methyl]acetamide 883229-85-4P, N-[[[(5S)-3-[3,5-Difluoro-4-[6-(1H-1,2,3-triazol-1-yl)pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide 883229-86-5P, N-[[[(5S)-3-[3,5-Difluoro-4-[6-(4-phenyl-1H-imidazol-1-yl)pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide 883229-98-9P, N-[[[3-[3-Fluoro-4-[6-(5-phenyl-1H-tetrazol-1-yl)pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide 883230-01-1P,

N-[[(5S)-3-[3,5-Difluoro-4-[6-(4-pyridin-3-yl-1H-imidazol-1-yl)pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide 883230-02-2P
 , N-[[(5S)-3-[3,5-Difluoro-4-[6-(5-phenyl-1H-tetrazol-1-yl)pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide 883230-14-6P
 , N-[[(5S)-3-[4-[6-[4-(Difluoromethyl)-1H-imidazol-1-yl]pyridin-3-yl]-3,5-difluorophenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide 883230-21-5P,
 N-[[(5S)-3-[3,5-Difluoro-4-[6-[4-(E)-(methoxyimino)methyl]-1H-imidazol-1-yl]pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide 883230-22-6P,
 N-[[(5S)-3-[3,5-Difluoro-4-[6-(4-formyl-1H-imidazol-1-yl)pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide 883230-23-7P
 , N-[[(5S)-3-[4-[6-(4-Cyano-1H-imidazol-1-yl)pyridin-3-yl]-3,5-difluorophenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide 883230-24-8P,
 Methyl 1-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl]-2,6-difluorophenyl]pyridin-2-yl]-1H-imidazole-4-carboxylate 883230-25-9P,
 N-[[(5S)-3-[3,5-Difluoro-4-[6-[4-(E)-(hydroxyimino)methyl]-1H-imidazol-1-yl]pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide 883230-36-2P,
 N-[[(5S)-3-[3,5-Difluoro-4-[6-[5-(4-fluorophenyl)-1H-tetrazol-1-yl]pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide 883230-40-8P,
 N-[[(5S)-3-[3,5-Difluoro-4-[6-[4-(hydroxymethyl)-1H-imidazol-1-yl]pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide 883230-43-1P,
 tert-Butyl [[(5R)-3-[3,5-difluoro-4-[6-(1H-1,2,4-triazol-1-yl)pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl] (isoxazol-3-yl) carbamate 883230-44-2P,
 tert-Butyl [[(5R)-3-[3-fluoro-4-[6-(1,3-oxazol-5-yl)pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl] (isoxazol-3-yl) carbamate 883230-50-0P,
 N-[[(5S)-3-[3,5-Difluoro-4-[6-(1H-1,2,4-triazol-1-yl)pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]ethanethioamide 883230-53-3P,
 Methyl [[(5S)-3-[3,5-difluoro-4-[6-(1H-1,2,4-triazol-1-yl)pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl] carbamate 883230-56-6P,
 N-[[(5S)-3-[3,5-Difluoro-4-[6-(1H-1,2,4-triazol-1-yl)pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]thiourea 883230-57-7P,
 N-[[(5S)-3-[3,5-Difluoro-4-[6-(1H-1,2,4-triazol-1-yl)pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]-N'-methylthiourea
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of phenyl-substituted oxazolidinone derivs. as antimicrobials)

RN 883229-59-2 CAPLUS

CN Acetamide, N-[[(5S)-3-[3,5-difluoro-4-[6-[3-(hydroxymethyl)-1H-pyrrol-1-yl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 883229-71-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3,5-difluoro-4-[6-[5-(4-oxazolyl)-2-furanyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 883229-72-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3,5-difluoro-4-[6-[5-(4-oxazolyl)-2-thienyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 883229-73-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3,5-difluoro-4-[6-[3-[(E)-(hydroxyimino)methyl]-1H-pyrrol-1-yl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

11/539,486


Absolute stereochemistry.
Double bond geometry as shown.



RN 883229-76-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3,5-difluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 883229-77-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3,5-difluoro-4-[6-(1H-imidazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 883229-78-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3,5-difluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

11/539,486


Absolute stereochemistry.



RN 883229-82-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3,5-difluoro-4-[6-(5-methyl-1,3,4-oxadiazol-2-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 883229-83-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-(5-amino-1,3,4-thiadiazol-2-yl)-3-pyridinyl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




11/539,486

RN 883229-85-4 CAPLUS

CN Acetamide, N-[[(5S)-3-[3,5-difluoro-4-[6-(1H-1,2,3-triazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 883229-86-5 CAPLUS


CN Acetamide, N-[[(5S)-3-[3,5-difluoro-4-[6-(4-phenyl-1H-imidazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 883229-98-9 CAPLUS

CN Acetamide, N-[[3-[3-fluoro-4-[6-(5-phenyl-1H-tetrazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 883230-01-1 CAPLUS

CN Acetamide, N-[[(5S)-3-[3,5-difluoro-4-[6-[4-(3-pyridinyl)-1H-imidazol-1-yl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

11/539,486


Absolute stereochemistry.



RN 883230-02-2 CAPLUS

CN Acetamide, N-[[(5S)-3-[3,5-difluoro-4-[6-(5-phenyl-1H-tetrazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 883230-14-6 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-[6-[4-(difluoromethyl)-1H-imidazol-1-yl]-3-pyridinyl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 883230-21-5 CAPLUS

CN Acetamide, N-[[(5S)-3-[3,5-difluoro-4-[6-[4-[(E)-(methoxyimino)methyl]-1H-

11/539,486

imidazol-1-yl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 883230-22-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3,5-difluoro-4-[6-(4-formyl-1H-imidazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 883230-23-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-(4-cyano-1H-imidazol-1-yl)-3-pyridinyl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 883230-24-8 CAPLUS

11/539,486

CN 1H-Imidazole-4-carboxylic acid, 1-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,6-difluorophenyl]-2-pyridinyl]-, methyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 883230-25-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3,5-difluoro-4-[6-[4-[(E)-(hydroxyimino)methyl]-1H-imidazol-1-yl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 883230-36-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3,5-difluoro-4-[6-[5-(4-fluorophenyl)-1H-tetrazol-1-yl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 883230-40-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3,5-difluoro-4-[6-[4-(hydroxymethyl)-1H-imidazol-1-yl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 883230-43-1 CAPLUS

CN Carbamic acid, [[[(5R)-3-[3,5-difluoro-4-[6-(1H-1,2,4-triazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-3-isoxazolyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 883230-44-2 CAPLUS

CN Carbamic acid, [[(5R)-3-[3-fluoro-4-[6-(5-oxazolyl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-3-isoxazolyl-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 883230-50-0 CAPLUS

CN Ethanethioamide, N-[[(5S)-3-[3,5-difluoro-4-[6-(1H-1,2,4-triazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




11/539,486

RN 883230-53-3 CAPLUS

CN Carbamic acid, [[(5S)-3-[3,5-difluoro-4-[6-(1H-1,2,4-triazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 883230-56-6 CAPLUS

CN Thiourea, [[(5S)-3-[3,5-difluoro-4-[6-(1H-1,2,4-triazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 883230-57-7 CAPLUS


CN Thiourea, N-[[[(5S)-3-[3,5-difluoro-4-[6-(1H-1,2,4-triazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-N'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 883231-21-8P, tert-Butyl [5-[4-[(5R)-5-[(acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl]-2,6-difluorophenyl]pyridin-2-yl]carbamate
 883231-22-9P, N-[[[(5S)-3-[4-(6-Aminopyridin-3-yl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
 883231-29-6P, tert-Butyl [[(5R)-3-[3,5-difluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl](isoxazol-3-yl)carbamate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of phenyl-substituted oxazolidinone derivs. as antimicrobials)
 RN 883231-21-8 CAPLUS
 CN Carbamic acid, [5-[4-[(5R)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,6-difluorophenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 883231-22-9 CAPLUS
 CN Acetamide, N-[[[(5S)-3-[4-(6-amino-3-pyridinyl)-3,5-difluorophenyl]-2-oxo-5-

11/539,486

oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 883231-29-6 CAPLUS

CN Carbamic acid, [[(5R)-3-[3,5-difluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]-3-isoxazolyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:193594 CAPLUS

DN 144:274261

TI Preparation of 3-biphenyl-2-oxazolidone derivatives as antiinfective agents

IN Lou, Rongliang; Bhattacharjee, Ashoke; Chen, Yi; Chen, Shili; Adegboyega, Oyelere K.; Wang, Deping; Wu, Yusheng; Zhou, Jiacheng

PA Rib-X Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 89 pp.

CODEN: PIXXD2

DT Patent


LA English

11/539,486

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006022794	A1	20060302	WO 2004-US39966	20041201
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2004-591771P	P	20040728		
OS	MARPAT 144:274261				
IT	877876-06-7P 877876-13-6P 877876-17-0P 877876-48-7P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(drug candidate; preparation of 3-biphenyl-2-oxazolidone derivs. as antiinfective agents)				
RN	877876-06-7 CAPLUS				
CN	Acetamide, N-[[[(5S)-3-[4-[6-[[[(cyanomethyl)amino]methyl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




RN 877876-13-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-[(1S)-2-cyano-1-hydroxyethyl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 877876-17-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-[[[(cyanoamino)(methylamino)methylene]amino]methyl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 877876-48-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-[[[2-(methylthio)ethyl]amino]methyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CN(C)C(=O)S[C@H]1CC(=O)N1c2ccc(cc2F)c3ccc(cc3NCCSC)nc4ccccc4

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 3-biphenyl-2-oxazolidone derivs. as antiinfective agents)

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(6-formyl-3-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


CC(=O)N[C@H]1CCN(C1C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N)C4=CC=CC=C4F

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 3-biphenyl-2-oxazolidone derivs. as antiinfective agents)

CN Acetamide, N-[[(5S)-3-[4-[6-(aminomethyl)-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

11/539,486


Absolute stereochemistry.



RN 877876-69-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-(chloromethyl)-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:167026 CAPLUS

DN 144:233063

TI Preparation of oxazolidinone derivatives as antimicrobials

IN Das, Biswajit; Ahmed, Shahadat; Yadav, Ajay Singh; Ghosh, Soma; Rattan, Ashok

PA Ranbaxy Laboratories Limited, India

SO PCT Int. Appl., 20 pp.

CODEN: PIXXD2

11/539,486

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006018682	A2	20060223	WO 2005-IB2226	20050727
	WO 2006018682	A3	20060706		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2004-600495P P 20040811
OS CASREACT 144:233063; MARPAT 144:233063
IT 876727-56-9P 876727-57-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-aryloxazolidinonylmethylacetamide derivs. as antimicrobial agents)

RN 876727-56-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3,5-difluoro-4-[5-fluoro-6-(1H-tetrazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 876727-57-0 CAPLUS


CN Acetamide, N-[[[(5S)-3-[3,5-difluoro-4-[6-(1H-tetrazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:115338 CAPLUS
 DN 144:141973
 TI Effects of acute renal failure on the pharmacokinetics of DA-7867, a new oxazolidinone, in rats
 AU Bae, Soo K.; Kwon, Jong W.; Kim, Won B.; Lee, Inchul; Lee, Myung G.
 CS College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, S. Korea
 SO Biopharmaceutics & Drug Disposition (2006), 27(1), 29-37
 CODEN: BDDID8; ISSN: 0142-2782
 PB John Wiley & Sons Ltd.
 DT Journal
 LA English
 IT 380382-38-7, DA-7867
 RL PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (effects of acute renal failure on pharmacokinetics of DA-7867, a new oxazolidinone, in rats)
 RN 380382-38-7 CAPLUS
 CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 6 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1292080 CAPLUS

11/539,486

DN 144:36354
TI Preparation of 3-[4-(pyridin-3-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)oxazolidin-2-ones as antibacterial agents
IN Gravestock, Michael Barry; Reck, Folkert; Zhou, Fei
PA Astrazeneca UK Limited, UK
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005116023	A1	20051208	WO 2005-GB2055	20050524
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	GB 2004-11592	A	20040525		
	GB 2005-53	A	20050105		
OS	MARPAT 144:36354				
IT	380382-39-8				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(preparation of 3-[4-(pyridin-3-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)oxazolidin-2-ones as antibacterial agents)				
RN	380382-39-8	CAPLUS			
CN	Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1291974 CAPLUS
DN 144:36352
TI Preparation of 3-[4-(pyridin-3-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)oxazolidin-2-ones as antibacterial agents

11/539,486


IN Gravestock, Michael Barry; Reck, Folkert; Zhou, Fei
PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005116022	A1	20051208	WO 2005-GB2051	20050524
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	GB 2004-11593	A	20040525		
	GB 2005-54	A	20050105		
OS	MARPAT 144:36352				
IT	380382-39-8				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(preparation of 3-[4-(pyridin-3-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)oxazolidin-2-ones as antibacterial agents)				
RN	380382-39-8 CAPLUS				
CN	Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1093808 CAPLUS
DN 144:3148
TI In vitro susceptibility of Mycobacterium tuberculosis clinical isolates to garenoxacin and DA-7867
AU Vera-Cabrera, Lucio; Castro-Garza, Jorge; Rendon, Adrian; Ocampo-Candiani, Jorge; Welsh, Oliverio; Choi, Sung Hak; Blackwood, Kym; Molina-Torres, Carmen

11/539,486

CS Servicio de Dermatologia, Hospital Universitario "Jose E. Gonzalez",
Monterrey, 64460, Mex.
SO Antimicrobial Agents and Chemotherapy (2005), 49(10), 4351-4353
CODEN: AMACCQ; ISSN: 0066-4804
PB American Society for Microbiology
DT Journal
LA English
IT 380382-38-7, DA-7867
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(in vitro susceptibility of Mycobacterium tuberculosis clin. isolates
to garenoxacin and DA-7867)
RN 380382-38-7 CAPLUS
CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-
pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

~~Absolute stereochemistry.~~



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:588915 CAPLUS
DN 143:97346
TI Preparation of halogenated biaryl oxazolidinones as antiinflammatory
agents
IN Chen, Shili; Zhou, Jiacheng; Wu, Yunsheng; Wang, Deping; Salvino, Joseph
M.; Oyelere, Adegboyega K.; Lou, Rongliang
PA Rib-X Pharmaceuticals, Inc., USA; Bhattacharjee, Ashoke; Chen, Yi
SO PCT Int. Appl., 123 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005061468	A1	20050707	WO 2004-US39988	20041201
	WO 2005061468	C1	20050909		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				

EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

US 2005153971	A1	20050714	US 2004-1446	20041201
US 2006148869	A1	20060706	US 2006-362133	20060223
PRAI US 2003-530371P	P	20031217		
US 2004-576267P	P	20040602		
US 2004-1446	A3	20041201		


OS MARPAT 143:97346
 IT 856908-56-0P 856908-57-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of halogenated biaryl oxazolidinones as antiinflammatory
 agents)
 RN 856908-56-0 CAFLUS
 CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-[[(3-fluoropropyl) amino] methyl]-3-
 pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 856908-57-1 CAPLUS
 CN Acetamide, N-[[(5S)-3-[4-[6-[[bis (3-fluoropropyl) amino] methyl]-3-
 pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



IT 847490-56-6P 847490-57-7P 847490-58-8P
847490-59-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of halogenated biaryl oxazolidinones as antiinflammatory
agents)

RN 847490-56-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(hydroxymethyl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 847490-57-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-(azidomethyl)-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

11/539,486

Absolute stereochemistry.





RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:564663 CAPLUS
DN 143:97343
TI Preparation of oxazolidinone broad-spectrum antibiotics
IN Rhee, Jae Keol; Im, Weon Bin; Cho, Chong Hwang; Choi, Sung Hak; Lee, Tae Ho
PA Dong-A Pharm.Co., Ltd., S. Korea
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005058886	A1	20050630	WO 2004-KR3327	20041217
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004299413	A1	20050630	AU 2004-299413	20041217
PRAI	KR 2003-93342	A	20031218		
	KR 2004-58809	A	20040727		
	WO 2004-KR3327	W	20041217		
OS	MARPAT 143:97343				
IT	856866-58-5P 856866-61-0P 856866-63-2P				
	856866-66-5P 856866-68-7P 856866-70-1P				
	856866-78-9P 856866-91-6P				

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

11/539,486

(Preparation); USES (Uses)

(preparation of oxazolidinone broad-spectrum antibiotics effective against
MRSA and VRE)

RN 856866-58-5 CAPLUS


CN Glycine, [1-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-5-oxo-3-pyrrolidinyl]methyl ester,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 856866-57-4

CMF C24 H26 F N5 O6


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 856866-61-0 CAPLUS

CN Glycine, [1-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-1H-1,2,3-triazol-4-yl]methyl ester,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 856866-60-9

CMF C22 H22 F N7 O5

Absolute stereochemistry.


11/539,486



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 856866-63-2 CAPLUS


CN Glycine, [3-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-5-isoxazolyl]methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 856866-62-1

CMF C23 H22 F N5 O6

Absolute stereochemistry.




11/539,486

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 856866-66-5 CAPLUS


CN Glycine, 1-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-2-oxo-3-pyrrolidinyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 856866-65-4

CMF C23 H24 F N5 O6


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 856866-68-7 CAPLUS


CN Glycine, [3-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-1,2,4-oxadiazol-5-yl]methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

11/539,486


CRN 856866-67-6
CMF C22 H21 F N6 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 856866-70-1 CAPLUS
CN Glycine, [3-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 856866-69-8
CMF C23 H24 F N5 O6

Absolute stereochemistry.




11/539,486

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 856966-79-9 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-[6-(4,5-dimethyl-2-oxazolyl)-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 856866-91-6 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-(2H-1,2,3-triazol-2-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 380381-17-9

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of oxazolidinone broad-spectrum antibiotics effective against MRSA and VRE)

11/539,486

RN 380381-17-9 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-(1H-imidazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 856867-62-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of oxazolidinone broad-spectrum antibiotics effective against MRSA and VRE)

RN 856867-62-4 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-[4-(hydroxymethyl)-2-oxo-1-pyrrolidinyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:494332 CAPLUS

DN 143:22926

TI In vitro and in vivo activities of DA-7867, a new oxazolidinone, against aerobic Gram-positive bacteria


AU Yoon, Eun Jeong; Jo, Jeong Woo; Choi, Sung Hak; Lee, Tae Ho; Rhee, Jae Keol; Yoo, Moochi; Shim, Mi Ja; Choi, Eung Chil

CS College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 151-742, S. Korea

11/539,486

SO Antimicrobial Agents and Chemotherapy (2005), 49(6), 2498-2500
CODEN: AMACCQ; ISSN: 0066-4804
PB American Society for Microbiology
DT Journal
LA English
IT 380382-38-7, DA-7867
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(antibiotic activity of oxazolidinone DA-7867 against gram-pos.
bacteria)
RN 380382-38-7 CAPLUS
CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-
pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:465155 CAPLUS
DN 143:186490
TI Pharmacokinetic changes of DA-7867, a new oxazolidinone, after intravenous
and oral administration to rats with short-term and long-term diabetes
mellitus induced by streptozotocin
AU Bae, Soo K.; Yang, Si H.; Lee, Shin J.; Kwon, Jong W.; Kim, Won B.; Lee,
Duk C.; Lee, Myung G.
CS College of Pharmacy and Research Institute of Pharmaceutical Sciences,
Seoul National University, Shinlim-Dong, Kwanak-Gu, Seoul, 151-742, S.
Korea
SO European Journal of Pharmaceutical Sciences (2005), 25(2-3), 337-345
CODEN: EPSCED; ISSN: 0928-0987
PB Elsevier B.V.
DT Journal
LA English
IT 380382-38-7, DA-7867
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(pharmacokinetic changes of DA-7867, a new oxazolidinone, after i.v.
and oral administration to rats with short-term and long-term diabetes
mellitus induced by streptozotocin)
RN 380382-38-7 CAPLUS
CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-
pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

11/539,486


Absolute stereochemistry.



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:282557 CAPLUS
DN 142:403416
TI Excretion and metabolism of DA-7867, a new oxazolidinone, in rats
AU Bae, Soo K.; Kim, Eun J.; Kwon, Jong W.; Kim, Won B.; Lee, Inchul; Lee, Myung G.
CS College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 151-742, S. Korea
SO Biopharmaceutics & Drug Disposition (2005), 26(2), 67-75
CODEN: BDDID8; ISSN: 0142-2782
PB John Wiley & Sons Ltd.
DT Journal
LA English
IT 380382-38-7, DA-7867
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(new oxazolidinone antibiotic DA-7867 excretion and metabolism in rats)
RN 380382-38-7 CAPLUS
CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:182657 CAPLUS

DN 142:280195

TI Preparation of biaryl heterocyclic compounds and methods of making and using the same in pharmaceutical applications

IN Zhou, Jiacheng; Bhattacharjee, Ashoke; Chen, Shili; Chen, Yi; Farmer, Jay J.; Goldberg, Joel A.; Hanselmann, Roger; Lou, Rongliang; Orbin, Alia; Oyelere, Adegboyega K.; Salvino, Joseph M.; Springer, Dane M.; Tran, Jennifer; Wang, Deping; Wu, Yusheng

PA Rib-X Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 259 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005019211	A2	20050303	WO 2004-US17101	20040602
	WO 2005019211	A3	20060330		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004267007	A1	20050303	AU 2004-267007	20040602
	CA 2528089	AA	20050303	CA 2004-2528089	20040602
	EP 1656370	A2	20060517	EP 2004-776193	20040602
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
	US 2005203147	A1	20050915	US 2005-118808	20050429
PRAI	US 2003-475430P	P	20030603		
	US 2003-475453P	P	20030603		
	US 2003-490855P	P	20030729		
	US 2003-529731P	P	20031215		
	US 2003-531584P	P	20031219		
	US 2004-859476	A1	20040602		
	WO 2004-US17101	W	20040602		
OS	MARPAT 142:280195				
IT	843673-51-8P 847489-20-7P 847489-21-8P				
	847490-27-1P 847490-31-7P 847491-33-2P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of biaryl heterocyclic compound as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents)				
RN	843673-51-8 CAPLUS				
CN	2-Pyridinecarboxamide, 5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



RN 847489-20-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1H-tetrazol-1-ylmethyl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847489-21-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1H-1,2,3-triazol-1-ylmethyl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 847490-27-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-[(4-oxazolylmethyl)amino]methyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


pyridinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)
Absolute stereochemistry.



Absolute stereochemistry.



Absolute stereochemistry.




IT 847490-97-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of biaryl heterocyclic compound as anti-infective,
anti-proliferative, anti-inflammatory, and prokinetic agents)
RN 847490-97-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(6-formyl-3-pyridinyl)phenyl]-2-oxo-5-

11/539,486

oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 847490-56-6P 847490-57-7P 847490-58-8P

847490-59-9P 847490-60-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of biaryl heterocyclic compound as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents)

RN 847490-56-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(hydroxymethyl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847490-57-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-(azidomethyl)-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

11/539,486


Absolute stereochemistry.



RN 847490-58-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-[(methylsulfonyl)oxy]methyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847490-59-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-(aminomethyl)-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 847490-60-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-[[4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl]methyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 15 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:120906 CAPLUS

DN 142:219289

TI Process for the synthesis of biaryl oxazolidinones

IN Wu, Yusheng; Chen, Shili; Chen, Yi; Hanselmann, Roger; Lou, Rongliang; Zhou, Jiacheng

PA Rib-X Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 110 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005012271	A2	20050210	WO 2004-US24339	20040728
	WO 2005012271	A3	20050929		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

US 2005043317 A1 20050224 US 2004-859476 20040602
 US 6969726 B2 20051129
 EP 1660465 A2 20060531 EP 2004-779405 20040728
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

US 2005203147 A1 20050915 US 2005-118808 20050429
 US 2005148869 A1 20060706 US 2006-362133 20060223
 PRAI US 2003-490855P P 20030729
 US 2003-529731P P 20031215
 US 2003-530371P P 20031217
 US 2003-531584P P 20031219
 US 2004-576163P P 20040602
 US 2004-859476 A 20040602
 US 2003-475430P P 20030603
 US 2003-475453P P 20030603
 US 2004-576267P P 20040602
 WO 2004-US24339 W 20040728
 US 2004-1446 A3 20041201

OS CASREACT 142:219289; MARPAT 142:219289


IT 843673-51-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (process for synthesis of biaryloxazolidinones by Suzuki coupling
 reaction of arylboronic acids with aryl halides or sulfonates)

RN 843673-51-8 CAPLUS

CN 2-Pyridinecarboxamide, 5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




AN 2005:58198 CAPLUS
 DN 142:155938
 TI Preparation of cyclopropyl group substituted oxazolidinones as antibiotics
 IN Fukuda, Yasumichi
 PA Merck & Co., Inc., USA; Kyorin Pharmaceutical Co., Ltd.
 SO PCT Int. Appl., 85 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005005420	A1	20050120	WO 2004-US20737	20040629
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, IF, II, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004256085	A1	20050120	AU 2004-256085	20040629
	CA 2529293	AA	20050120	CA 2004-2529293	20040629
	EP 1654259	A1	20060510	EP 2004-777199	20040629
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	CN 1816545	A	20060809	CN 2004-80018905	20040629
PRAI	US 2003-483904P	P	20030702		
	US 2004-546980P	P	20040224		
	WO 2004-US20737	W	20040629		
OS	CASREACT 142:155938; MARPAT 142:155938				
IT	827627-63-4P 827627-64-5P 827627-66-7P 827627-69-0P 827627-72-5P 827627-84-9P 827627-88-3P 827627-93-0P 827627-95-2P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (antibacterial agent; preparation of cyclopropyl-oxazolidinones as antibiotics)				
RN	827627-63-4 CAPLUS				
CN	Acetamide, N-[[[(5S)-3-[4-[6-(1-cyanocyclopropyl)-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.


11/539,486



RN 827627-64-5 CAPLUS

CN Carbamic acid, [1-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-pyridinyl]cyclopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827627-66-7 CAPLUS

CN Carbamic acid, [1-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]cyclopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 827627-69-0 CAPLUS

CN Cyclopropanecarboxylic acid, 1-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 827627-72-5 CAPLUS

CN Carbamic acid, [1-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,6-difluorophenyl]-2-pyridinyl]cyclopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 827627-84-9 CAPLUS

CN Carbamic acid, [[(5R)-3-[4-[6-[1-[(1,1-dimethylethoxy) carbonyl] amino] cyclopropyl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-3-isoxazolyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827627-88-3 CAPLUS

CN Carbamic acid, [[(5R)-3-[4-[6-(1-cyanocyclopropyl)-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-3-isoxazolyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

CC(C)(C)OC(=O)N1C=CN=C1CNC2OC(=O)N(C2)c3ccc(cc3-c4ccc5c(n4)C67C8C9C8C9C67)C#N

CN Carbamic acid, [(1 α ,5 α ,6 α)-3-[5-[4-[(5R)-5-
 [(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-
 azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX
 NAME)

CN Carbamic acid, [(1 α ,5 α ,6 α)-3-[5-[4-[(5R)-5-
[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-3-
azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX
NAME)

Absolute stereochemistry.



IT 827627-61-2P 827627-65-6P 827627-67-8P
 827627-68-9P 827627-70-3P 827627-73-6P
 827627-74-7P 827627-80-5P 827627-82-7P
 827627-94-1P 827627-96-3P 827628-08-0P
 827628-44-4P 827629-06-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antibacterial agent; preparation of cyclopropyl-oxazolidinones as antibiotics)

RN 827627-61-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-(1-cyanocyclopropyl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827627-65-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-(1-aminocyclopropyl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 827627-67-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-(1-aminocyclopropyl)-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827627-68-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-[1-[(dimethylamino)methyl]cyclopropyl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 827627-70-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-[1-(hydroxymethyl)cyclopropyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827627-73-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-(1-aminocyclopropyl)-3-pyridinyl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 827627-74-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-[1-(aminomethyl)cyclopropyl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827627-80-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-(1-cyanocyclopropyl)-3-pyridinyl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 827627-82-7 CAPLUS

CN Carbamic acid, [[[5R)-3-[4-[6-(1-cyanocyclopropyl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-3-isoxazolyl-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 827627-94-1 CAPLUS

CN Acetamide, N-[[[(5R)-3-[4-[6-[(1 α ,5 α ,6 α)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 827627-96-3 CAPLUS

CN Acetamide, N-[[[(5R)-3-[4-[6-[(1 α ,5 α ,6 α)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827628-08-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-(1-aminocyclopropyl)-5-fluoro-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 827628-44-4 CAPLUS

CN Carbamic acid, [[(5R)-3-[4-[6-(1-aminocyclopropyl)-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-3-isoxazolyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827629-06-1 CAPLUS

CN Cyclopropanecarboxylic acid, 1-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 17 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:55212 CAPLUS
DN 142:155937
TI Preparation of cyclopropyl group substituted oxazolidinones as antibiotics
IN Fukuda, Yasumichi
PA Merck & Co., Inc., USA; Kyorin Pharmaceutical Co., Ltd.
SO PCT Int. Appl., 170 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005005398	A2	20050120	WO 2004-US20734	20040629
	WO 2005005398	A3	20050428		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004256083	A1	20050120	AU 2004-256083	20040629
	CA 2530140	AA	20050120	CA 2004-2530140	20040629
	US 2005038092	A1	20050217	US 2004-878637	20040629
	EP 1646629	A2	20060419	EP 2004-777196	20040629
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
	CN 1816548	A	20060809	CN 2004-80019102	20040629
PRAI	US 2003-483904P	P	20030702		
	US 2004-546984P	P	20040224		

11/539,486


WO 2004-US20734 W 20040629
OS CASREACT 142:155937; MARPAT 142:155937
IT 831201-20-8P 831201-26-4P 831201-32-2P
831201-42-4P 831201-58-2P 831201-62-8P
831201-70-8P 831201-73-1P 831201-78-6P
831201-80-0P 831201-82-2P 831202-02-9P
831202-35-8P 831202-41-6P 831202-52-9P
831202-79-0P 831222-04-9P 831222-05-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(antibacterial agent; preparation of cyclopropyl-oxazolidinones as antibiotics)
RN 831201-20-8 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-pyridinyl]-6-cyano-, 1,1-dimethylethyl ester, (1 α ,5 α ,6 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-26-4 CAPLUS
CN Carbamic acid, [(1 α ,5 α ,6 β)-6-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-3-oxabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




11/539,486

RN 831201-32-2 CAPLUS

CN Carbamic acid, [(1 α ,5 α ,6 β)-6-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831201-42-4 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,6-difluorophenyl]-2-pyridinyl]-6-cyano-, 1,1-dimethylethyl ester, (1 α ,5 α ,6 β)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-58-2 CAPLUS

CN Carbamic acid, [(1 α ,5 α ,6 β)-6-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,6-difluorophenyl]-2-pyridinyl]-3-oxabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 831201-62-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-[(1 α ,5 α ,6 β)-6-cyano-3-thiabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831201-70-8 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[4-[(5R)-5-[[[(1,1-dimethylethoxy)carbonyl]-3-isoxazolylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester, (1 α ,5 α ,6 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831201-73-1 CAPLUS

CN Carbamic acid, [[(5R)-3-[4-[6-[(1 α , 5 α , 6 β)-6-cyano-3-oxabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-3-isoxazolyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831201-78-6 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[2-fluoro-4-[(5S)-2-oxo-5-[(1-oxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-2-pyridinyl-, 1,1-dimethylethyl ester, (1 α , 5 α , 6 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831201-80-0 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[4-[(5S)-5-
[[cyclopropylcarbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-
2-pyridinyl]-, 1,1-dimethylethyl ester, (1 α ,5 α ,6 β)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 831201-82-2 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[4-[(5S)-5-
[[difluoroacetyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-
pyridinyl]-, 1,1-dimethylethyl ester, (1 α ,5 α ,6 β)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 831202-02-9 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[2-fluoro-4-[(5S)-5-[(methoxycarbonyl)amino]methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester, (1 α ,5 α ,6 β)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 831202-35-8 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[4-[(5R)-5-[[[(1,1-dimethylethoxy)carbonyl]-3-isoxazolylamino]methyl]-2-oxo-3-oxazolidinyl]-2,6-difluorophenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester, (1 α ,5 α ,6 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-41-6 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[4-[(5S)-5-[[[(1R)-2,2-dichlorocyclopropyl]carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester, (1 α ,5 α ,6 β)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—OBu-t


RN 831202-52-9 CAPLUS

11/539,486

CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[(5S)-5-[4-[5-[[[(1R)-2,2-difluorocyclopropyl]carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester, (1 α ,5 α ,6 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 831202-79-0 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[2-fluoro-4-[(5S)-2-oxo-5-[(1-thioxoethyl)amino]methyl]-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester, (1 α ,5 α ,6 β)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 831222-04-9 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[4-[(5R)-5-[[[(1S)-2,2-dichlorocyclopropyl]carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester, (1 α ,5 α ,6 β)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—OBu-t


11/539,486

RN 831222-05-0 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[4-[(5S)-5-[[[(1S)-2,2-difluorocyclopropyl]carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester, (1 α ,5 α ,6 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—OBu-t

IT 831201-21-9P 831201-24-2P 831201-25-3P
831201-27-5P 831201-30-0P 831201-33-3P
831201-36-6P 831201-43-5P 831201-59-3P
831201-60-6P 831201-63-9P 831201-75-3P
831201-76-4P 831201-77-5P 831201-79-7P
831201-81-1P 831201-83-3P 831202-00-7P
831202-01-8P 831202-03-0P 831202-38-1P
831202-39-2P 831202-49-4P 831202-50-7P
831202-83-6P 831202-85-8P 831202-87-0P
831221-98-8P 831222-00-5P 831222-01-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antibacterial agent; preparation of cyclopropyl-oxazolidinones as antibiotics)


RN 831201-21-9 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-[6-[(1 α ,5 α ,6 β)-6-cyano-3-

11/539,486

azabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 831201-24-2 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-6-cyano-, 1,1-dimethylethyl ester, (1 α ,5 α ,6 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-25-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-[(1 α ,5 α ,6 β)-6-cyano-3-azabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

11/539,486




● HCl

RN 831201-27-5 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-[6-[(1 α , 5 α , 6 β)-6-amino-3-oxabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-30-0 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-[6-[(1 α , 5 α , 6 β)-6-cyano-3-oxabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 831201-33-3 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-[6-[(1 α ,5 α ,6 β)-6-amino-3-oxabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831201-36-6 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-[6-[(1 α ,5 α ,6 β)-6-cyano-3-oxabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-43-5 CAPLUS

11/539,486

CN Acetamide, N-[[(5S)-3-[4-[6-[(1 α ,5 α ,6 β)-6-cyano-3-azabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 831201-59-3 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-[6-[(1 α ,5 α ,6 β)-6-amino-3-oxabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-60-6 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-[6-[(1 α ,5 α ,6 β)-6-cyano-3-oxabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 831201-63-9 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-[6-[(1 α ,5 α ,6 β)-6-cyano-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-75-3 CAPLUS

CN Propanamide, N-[[(5S)-3-[4-[6-[(1 α ,5 α ,6 β)-6-cyano-3-oxabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 831201-76-4 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-[6-[(1 α , 5 α , 6 β)-6-cyano-3-oxabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-2,2-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-77-5 CAPLUS

CN Cyclopropanecarboxamide, N-[[(5S)-3-[4-[6-[(1 α , 5 α , 6 β)-6-cyano-3-oxabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 831201-79-7 CAPLUS

CN Propanamide, N-[[[(5S)-3-[4-[6-[(1 α ,5 α ,6 β)-6-cyano-3-azabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-81-1 CAPLUS

CN Cyclopropanecarboxamide, N-[[[(5S)-3-[4-[6-[(1 α ,5 α ,6 β)-6-cyano-3-azabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

11/539,486




● HCl

RN 831201-83-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-[(1 α ,5 α ,6 β)-6-cyano-3-azabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-2,2-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 831202-00-7 CAPLUS

CN Cyclopropanecarboxamide, 2,2-dichloro-N-[[[(5S)-3-[4-[6-[(1 α ,5 α ,6 β)-6-cyano-3-azabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 831202-01-8 CAPLUS

CN Cyclopropanecarboxamide, N-[[[(5S)-3-[4-[6-[(1 α ,5 α ,6 β)-6-cyano-3-azabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-2,2-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-03-0 CAPLUS

CN Carbamic acid, [[[(5S)-3-[4-[6-[(1 α ,5 α ,6 β)-6-cyano-3-azabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 831202-38-1 CAPLUS

CN Ethanethioamide, N-[[(5S)-3-[4-[6-[(1 α , 5 α , 6 β)-6-cyano-3-azabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-39-2 CAPLUS

CN Carbamothioic acid, [[(5S)-3-[4-[6-[(1 α , 5 α , 6 β)-6-cyano-3-azabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-, O-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 831202-49-4 CAPLUS

CN Cyclopropanecarboxamide, N-[[(5S)-3-[4-[6-[(1 α ,5 α ,6 β)-6-cyano-3-azabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-50-7 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-[6-[(1 α ,5 α ,6 β)-6-cyano-3-azabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2,2-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 831202-83-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-[(1 α , 5 α , 6 β)-6-cyano-3-azabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-85-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-[(1 α , 5 α , 6 β)-6-cyano-3-azabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 831202-87-0 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-[6-[(1 α ,5 α ,6 β)-6-cyano-3-azabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831221-98-8 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-[6-[(1 α ,5 α ,6 β)-6-cyano-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831222-00-5 CAPLUS

11/539,486

CN Cyclopropanecarboxamide, 2,2-dichloro-N-[[(5S)-3-[4-[6-
[(1 α ,5 α ,6 β)-6-cyano-3-azabicyclo[3.1.0]hex-6-yl]-3-
pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-, (1S)- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 831222-01-6 CAPLUS

CN Cyclopropanecarboxamide, N-[[(5S)-3-[4-[6-[(1 α ,5 α ,6 β)-6-
cyano-3-azabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-
oxazolidinyl)methyl]-2,2-difluoro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 831202-40-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(intermediate; preparation of cyclopropyl-oxazolidinones as antibiotics)

RN 831202-40-5 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[2-fluoro-4-
[(5S)-5-[(methoxythioxomethyl)amino]methyl]-2-oxo-3-oxazolidinyl]phenyl]-
2-pyridinyl]-, 1,1-dimethylethyl ester, (1 α ,5 α ,6 β)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 18 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:891809 CAPLUS
 DN 142:52091
 TI Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring
 AU Jo, Yeong Woo; Im, Weon Bin; Rhee, Jae Keol; Shim, Mi Ja; Kim, Won Bae; Choi, Eung Chil
 CS College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 151-742, S. Korea
 SO Bioorganic & Medicinal Chemistry (2004), 12(22), 5909-5915
 CODEN: BMECEP; ISSN: 0968-0896
 PB Elsevier Ltd.
 DT Journal
 LA English
 OS CASREACT 142:52091
 IT 380381-17-9P 380382-23-0P 380382-28-5P
 380382-35-4P 380382-37-6P 380382-38-7P
 380382-39-8P 380382-45-6P 380382-52-5P
 811464-21-8P 811464-22-9P 811464-23-0P
 RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroarom. ring)
 RN 380381-17-9 CAPLUS
 CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1H-imidazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 380382-23-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1H-1,2,4-triazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 380382-28-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(4-methyl-1H-imidazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380382-35-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1H-tetrazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 380382-37-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1,2,4-oxadiazol-3-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 380382-38-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380382-39-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 380382-45-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1H-1,2,3-triazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 380382-52-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 811464-21-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1-methyl-1H-pyrazol-3-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 811464-22-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-{6-(1H-pyrazol-1-yl)-3-pyridinyl]phenyl}-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 811464-23-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-{6-(5-methyl-1H-tetrazol-1-yl)-3-pyridinyl]phenyl}-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 19 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN

11/539,486

AN 2004:756715 CAPLUS
DN 141:260739
TI Preparation of hydroxymethyl dihydroisoxazole derivatives useful as
antibiotic agents
IN Gravestock, Michael Barry; Hales, Neil James; Carcanague, Daniel Robert
PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004078753	A1	20040916	WO 2004-GB730	20040224
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004218206	A1	20040916	AU 2004-218206	20040224
	CA 2517706	AA	20040916	CA 2004-2517706	20040224
	EP 1599471	A1	20051130	EP 2004-713945	20040224
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2004007835	A	20060214	BR 2004-7835	20040224
	CN 1753888	A	20060329	CN 2004-80005423	20040224
	NO 2005004523	A	20051201	NO 2005-4523	20050930
PRAI	GB 2003-4723	A	20030301		
	GB 2003-18607	A	20030808		
	WO 2004-GB730	W	20040224		
OS	MARPAT 141:260739				
IT	756873-55-9P 756873-56-0P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of hydroxymethyl dihydroisoxazole derivs. useful as antibiotic agents)				
RN	756873-55-9 CAPLUS				
CN	Acetamide, N-[[(5S)-3-[4-[6-[(5S)-4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



11/539,486

RN 756873-56-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[6-[(5R)-4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:743397 CAPLUS
DN 141:235628
TI Effects of bacterial lipopolysaccharide on the pharmacokinetics of
DA-7867, a new oxazolidinone, in rats
AU Soo, K. Bae; Lee, Shin J.; Kwon, Jong W.; Kim, Won B.; Lee, Inchul; Lee,
Myung G.
CS College of Pharmacy and Research Institute of Pharmaceutical Sciences,
Seoul National University, Seoul, 151-742, S. Korea
SO Journal of Pharmaceutical Sciences (2004), 93(9), 2364-2373
CODEN: JPMSAE; ISSN: 0022-3549
PB Wiley-Liss, Inc.
DT Journal
LA English
IT 380382-38-7, DA-7867
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological
study); USES (Uses)
(effects of bacterial lipopolysaccharide on pharmacokinetics of
DA-7867)
RN 380382-38-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-
pyridinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:550954 CAPLUS

DN 141:89082

TI Preparation of 3-aryloxazolidinone antibacterial agents

IN Gravestock, Michael Barry; Hales, Neil James; Turner, Paul

PA Astrazeneca AB, Swed.; Astrazeneca UK Limited

SO PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004056816	A1	20040708	WO 2003-GB5444	20031215
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003292420	A1	20040714	AU 2003-292420	20031215
	EP 1572687	A1	20050914	EP 2003-767998	20031215
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006514647	T2	20060511	JP 2004-561615	20031215
	US 2006116389	A1	20060601	US 2005-539484	20050617
PRAI	GB 2002-29522	A	20021219		
	WO 2003-GB5444	W	20031215		
OS	MARPAT 141:89082				
IT	716380-61-9P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(Preparation of 3-aryloxazolidinone antibacterial agents)				
RN	716380-61-9 CAPLUS				
CN	Carbamic acid, [[(5R)-3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-3-isoxazoly-1-				

11/539,486

1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 716380-65-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(Preparation of 3-aryloxazolidinone antibacterial agents)

RN 716380-65-3 CAPLUS

CN Carbamic acid, [[[5R)-3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1,2,5-thiadiazol-3-yl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:546504 CAPLUS

DN 141:89092

TI A preparation of oxazolidinone derivatives, useful as antibacterial agents

IN Gravestock, Michael Barry; Hales, Neil James; Reck, Folkert; Zhou, Fei

PA Astrazeneca AB, Swed.; Astrazeneca UK Limited

SO PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI WO 2004056819 A1 20040708 WO 2003-GB5498 20031215
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2003292426 A1 20040714 AU 2003-292426 20031215
 EP 1575944 A1 20050921 EP 2003-768004 20031215
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2006512353 T2 20060413 JP 2004-561627 20031215
 US 2006052399 A1 20060309 US 2005-539486 20050617
 PRAI GB 2002-29521 A 20021219
 WO 2003-GB5498 W 20031215

OS MARPAT 141:89092

IT 717123-26-7P 717123-29-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxazolidinone derivs., useful as antibacterial agents)

RN 717123-26-7 CAPLUS

CN Carbamic acid, [[(5S)-3-[3-fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 717123-29-0 CAPLUS

CN Cyclopropanecarboxamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:478987 CAPLUS
DN 141:370
TI Effects of protein-calorie malnutrition on the pharmacokinetics of
DA-7867, a new oxazolidinone, in rats
AU Bae, Soo Kyung; Lee, Shin Jung; Kwon, Jong Won; Kim, Won Bae; Lee, Myung
Gull
CS College of Pharmacy and Research Institute of Pharmaceutical Sciences,
Seoul National University, Seoul, 151-742, S. Korea
SO Journal of Pharmacy and Pharmacology (2004), 56(5), 635-642
CODEN: JPPMAB; ISSN: 0022-3573
PB Pharmaceutical Press
DT Journal
LA English
IT 380382-38-7, DA-7867
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological
study); USES (Uses)
(protein-calorie malnutrition on pharmacokinetics of DA-7867 in rats)
RN 380382-38-7 CAPLUS
CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-
pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 24 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:467903 CAPLUS
DN 141:38599
TI Preparation of oxazolidinone/isoxazoline derivatives as antibacterial agents
IN Carcanague, Daniel Robert; Gravestock, Michael Barry; Hales, Neil James; Hauck, Sheila Irene; Weber, Thomas Peter
PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
SO PCT Int. Appl., 185 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004048392	A1	20040610	WO 2003-GB5087	20031124
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2507468	AA	20040610	CA 2003-2507468	20031124
	AU 2003302404	A1	20040618	AU 2003-302404	20031124
	EP 1567532	A1	20050831	EP 2003-811807	20031124
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003016688	A	20051018	BR 2003-16688	20031124
	CN 1742015	A	20060301	CN 2003-80109196	20031124
	JP 2006508192	T2	20060309	JP 2005-510253	20031124
	NO 2005002534	A	20050822	NO 2005-2534	20050526
	US 2006116400	A1	20060601	US 2005-536686	20050527
PRAI	GB 2002-27702	A	20021128		
	GB 2003-4725	A	20030301		
	GB 2003-18608	A	20030808		
	WO 2003-GB5087	W	20031124		
OS	MARPAT 141:38599				
IT	702680-40-8P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(preparation of oxazolidinone/isoxazoline derivs. as antibacterial agents)				
RN	702680-40-8 CAPLUS				
CN	Acetamide, N-[[[3-[4-[6-[(5S)-5-(chloromethyl)-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




IT 702680-44-2P 702680-81-7P, N-[[[(5S)-3-[3-Fluoro-4-[6-[5,5-bis(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of oxazolidinone/isoxazoline derivs. as antibacterial agents)
 RN 702680-44-2 CAPLUS
 CN Acetamide, N-[[[3-[4-[6-[(5S)-4,5-dihydro-5-(4-morpholinylmethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702680-81-7 CAPLUS
 CN Acetamide, N-[[[(5S)-3-[4-[6-[4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 702680-42-0


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of oxazolidinone/isoxazoline derivs. as antibacterial agents)

RN 702680-42-0 CAPLUS

CN Acetamide, N-[[3-[4-[6-[(5S)-4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:393883 CAPLUS

DN 140:385484

TI Pharmacokinetics, blood partition and protein binding of DA-7867, a new oxazolidinone

AU Bae, Soo K.; Chung, Won-S.; Kim, Eun J.; Rhee, Jae K.; Kwon, Jong W.; Kim, Won B.; Lee, Myung G.

CS College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 151-742, S. Korea

SO Biopharmaceutics & Drug Disposition (2004), 25(3), 127-135
CODEN: BDDID8; ISSN: 0142-2782

PB John Wiley & Sons Ltd.

DT Journal

LA English

IT 380382-38-7, DA-7867


11/539,486

RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacokinetics, blood partition and protein binding of DA-7867, a new oxazolidinone)

RN 380382-38-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 26 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:374761 CAPLUS

DN 141:422221

TI In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria. [Erratum to document cited in CA140:232388]

AU Yong, Dongeun; Yum, Jong Hwa; Lee, Kyungwon; Chong, Yunsop; Choi, Sung Hak; Rhee, Jae Keol

CS Department of Laboratory Medicine, Research Institute of Bacterial Resistance, and Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine, Seoul, S. Korea

SO Antimicrobial Agents and Chemotherapy (2004), 48(5), 1918
CODEN: AMACCQ; ISSN: 0066-4804

PB American Society for Microbiology

DT Journal

LA English


IT 380382-38-7, DA-7867

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in vitro activities of novel oxazolidinone DA-7867 against recent clin. isolates of aerobic and anaerobic bacteria (Erratum))

RN 380382-38-7 CAPLUS


CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 27 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:284289 CAPLUS
 DN 141:274
 TI Liquid chromatography-tandem mass spectrometry for the determination of a new oxazolidinone antibiotic DA-7867 in human plasma
 AU Ji, Hye Young; Lee, Hye Won; Chang, Seung Goo; Lee, Jong Jin; Rhee, Jae Keol; Kim, Won Bae; Lee, Hye Suk
 CS Drug Metabolism and Bioanalysis Laboratory, College of Pharmacy and Medicinal Resources Research Center, Wonkwang University, Iksan, 570-749, S. Korea
 SO Biomedical Chromatography (2004), 18(2), 86-89
 CODEN: BICHE2; ISSN: 0269-3879
 PB John Wiley & Sons Ltd.
 DT Journal
 LA English
 IT 380382-38-7, DA-7867
 RL: ANT (Analyte); ANST (Analytical study)
 (liquid chromatog.-tandem mass spectrometry for the determination of a new oxazolidinone antibiotic DA-7867 in human plasma)
 RN 380382-38-7 CAPLUS
 CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 28 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:205277 CAPLUS
 DN 140:353540
 TI In vitro activities of new quinolones and oxazolidinones against
 Actinomadura madurae
 AU Vera-Cabrera, Lucio; Ochoa-Felix, Elsa Y.; Gonzalez, Gloria; Tijerina,
 Rolando; Choi, Sung H.; Welsh, Oliverio
 CS Laboratorio Interdisciplinario de Investigacion Dermatologica, Servicio de
 Dermatologia, Hospital Universitario, Monterrey, Mex.
 SO Antimicrobial Agents and Chemotherapy (2004), 48(3), 1037-1039
 CODEN: AMACCQ; ISSN: 0066-4804
 PB American Society for Microbiology
 DT Journal
 LA English
 IT 380382-38-7, DA-7867
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (in vitro activities of new quinolones and oxazolidinones against
 Actinomadura madurae)
 RN 380382-38-7 CAPLUS
 CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-
 pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 29 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:192959 CAPLUS
 DN 141:424135
 TI Microwave-assisted solid-phase organic synthesis (MA-SPOS) of
 oxazolidinone antimicrobials
 AU Combs, Andrew P.; Glass, Brian M.; Jackson, Sharon A.
 CS Incyte Corporation, Wilmington, DE, 19880-0500, USA
 SO Methods in Enzymology (2003), 369(Combinatorial Chemistry, Part B),
 223-231
 CODEN: MENZAU; ISSN: 0076-6879
 PB Elsevier
 DT Journal
 LA English
 OS CASREACT 141:424135
 IT 128311-89-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)


11/539,486

(solid-phase preparation of aryloxazolidinones as antimicrobials via reductive amination of BAL-resin with aminomethyl(iodophenyl)oxazolidinone followed by N-acetylation, Suzuki coupling with arylboronic acids and resin cleavage)

RN 128311-89-7 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[4-(3-pyridinyl)phenyl]-5-oxazolidinyl)methyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 30 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:143139 CAPLUS

DN 140:181437

TI Preparation of N-aryl-2-oxazolidinones and their derivatives as antibacterial agents

IN Gadwood, Robert C.; Ochoada, Jason M.

PA Pharmacia & Upjohn Company, USA

SO PCT Int. Appl., 50 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004014897	A1	20040219	WO 2003-US22486	20030801
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2491287	AA	20040219	CA 2003-2491287	20030801
	AU 2003259159	A1	20040225	AU 2003-259159	20030801
	US 2004072873	A1	20040415	US 2003-632742	20030801
	EP 1539745	A1	20050615	EP 2003-784775	20030801
	EP 1539745	B1	20060329		

11/539,486


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
BR 2003013400 A 20050712 BR 2003-13400 20030801
JP 2005537301 T2 20051208 JP 2004-527615 20030801
AT 321760 E 20060415 AT 2003-784775 20030801
PRAI US 2002-402783P P 20020812
WO 2003-US22486 W 20030801
OS MARPAT 140:181437
IT 380381-21-5P 658073-61-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of N-aryloxazolidinones as antibacterial agents)
RN 380381-21-5 CAPLUS
CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-(6-methoxy-3-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 658073-61-1 CAPLUS
CN Acetamide, N-[[[(5S)-3-[4-(6-methoxy-3-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 31 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:115661 CAPLUS
DN 140:263706
TI Pharmacokinetics of DA-7867, a new oxazolidinone, after intravenous or oral administration to rats: Intestinal first-pass effect
AU Bae, Soo K.; Chung, Won-Suk; Kim, Eun J.; Rhee, Jae K.; Kwon, Jong W.; Kim, Won B.; Lee, Myung G.
CS College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 151-742, S. Korea
SO Antimicrobial Agents and Chemotherapy (2004), 48(2), 659-662
CODEN: AMACQ; ISSN: 0066-4804
PB American Society for Microbiology
DT Journal
LA English
IT 380382-38-7, DA-7867
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacokinetics of DA-7867, a new oxazolidinone, after i.v. or oral administration to rats and intestinal first-pass effect)
RN 380382-38-7 CAPLUS
CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 32 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:115644 CAPLUS
DN 140:267451
TI In vitro activities of new antimicrobials against *Nocardia brasiliensis*
AU Vera-Cabrera, Lucio; Gonzalez, Eva; Choi, Sung H.; Welsh, Oliverio
CS Laboratorio Interdisciplinario de Investigacion Dermatologica, Servicio de
Dermatologia, Hospital Universitario, Monterrey, Nuevo Leon, Mex.
SO Antimicrobial Agents and Chemotherapy (2004), 48(2), 602-604
CODEN: AMACCQ; ISSN: 0066-4804
PB American Society for Microbiology
DT Journal
LA English
IT 380382-38-7, DA-7867
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in vitro activities of new antimicrobials against *Nocardia brasiliensis*)
RN 380382-38-7 CAPLUS
CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 33 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:54720 CAPLUS
 DN 140:232388
 TI In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria
 AU Yong, Dongeun; Yum, Jong Hwa; Lee, Kyungwon; Chong, Yunsop; Choi, Sung Hak; Rhee, Jae Keol
 CS Department of Laboratory Medicine, Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, S. Korea
 SO Antimicrobial Agents and Chemotherapy (2004), 48(1), 352-357
 CODEN: AMACCQ; ISSN: 0066-4804
 PB American Society for Microbiology
 DT Journal
 LA English
 IT 380382-38-7. DA-7867
 RJ: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (in vitro activities of the novel oxazolidinone DA-7867 against recent clin. isolates of aerobic and anaerobic bacteria)
 RN 380382-38-7 CAPLUS
 CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 34 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:686396 CAPLUS
 DN 140:52666
 TI High-performance liquid chromatographic analysis of DA-7867, a new oxazolidinone, in human plasma and urine and in rat tissue homogenates
 AU Bae, Soo Kyung; Kim, Eun Jung; Kwon, Jong Won; Kim, Won Bae; Lee, Myung Gull
 CS College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Kwanak-Gu, 151-742, S. Korea
 SO Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences (2003), 794(2), 397-403
 CODEN: JCBAAI; ISSN: 1570-0232
 PB Elsevier B.V.
 DT Journal
 LA English
 IT 380382-38-7, DA 7867


RL: ANT (Analyte); ANST (Analytical study)

(high-performance liquid chromatog. anal. of DA-7867, a new oxazolidinone, in human plasma and urine and in rat tissue homogenates)

RN 380382-38-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 35 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:605861 CAPLUS

DN 140:275915

TI Predicting Oral Absorption of Drugs: A Case Study with a Novel Class of Antimicrobial Agents

AU Hilgers, Allen R.; Smith, Donald P.; Biermacher, John J.; Day, Jeffrey S.; Jensen, Jana L.; Sims, Sandra M.; Adams, Wade J.; Friis, Janice M.; Palandra, Joe; Hosley, John D.; Shobe, Eric M.; Burton, Philip S.

CS Global Pharmaceutical Sciences, Drug Absorption and Transport, Pharmacia, Kalamazoo, MI, 49007, USA

SO Pharmaceutical Research (2003), 20(8), 1149-1155

CODEN: PHREEB; ISSN: 0724-8741

PB Kluwer Academic/Plenum Publishers

DT Journal

LA English


IT 380382-50-3, PNU 184421

RL: PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(predicting oral absorption of oxazolidinones)

RN 380382-50-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-(6-cyano-3-pyridinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 36 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:221667 CAPLUS
DN 138:238171
TI Preparation of oxazolidinones and/or isoxazolines as antibacterial agents
IN Gravestock, Michael Barry; Hales, Neil James; Swain, Michael Lingard;
Hauck, Sheila Irene; Mills, Stuart Dennett
PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
SO PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003022824	A1	20030320	WO 2002-GB4120	20020909
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
CA 2459766	AA	20030320	CA 2002-2459766	20020909
EP 1427711	A1	20040616	EP 2002-765019	20020909
EP 1427711	B1	20050713		
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK	
BR 2002012458	A	20041019	BR 2002-12458	20020909
JP 2005507386	T2	20050317	JP 2003-526899	20020909
US 2005107435	A1	20050519	US 2003-489266	20020909
NZ 531621	A	20050624	NZ 2002-531621	20020909
CN 1639136	A	20050713	CN 2002-822327	20020909
AT 299502	E	20050715	AT 2002-765019	20020909
PT 1427711	T	20051130	PT 2002-765019	20020909

11/539,486


ES 2244802 T3 20051216 ES 2002-2765019 20020909
ZA 2004001888 A 20050418 ZA 2004-1888 20040308
NO 2004001428 A 20040608 NO 2004-1428 20040405
HK 1065789 A1 20051230 HK 2004-108506 20041029
PRAI GB 2001-21942 A 20010911
GB 2002-15420 A 20020704
WO 2002-GB4120 W 20020909
OS MARPAT 138:238171
IT 501940-85-8P, N-[[[(5S)-3-[4-[2-[5-(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl]pyrid-5-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of oxazolidinones and/or isoxazolines as antibacterial agents)
RN 501940-85-8 CAPLUS
CN Acetamide, N-[[[(5S)-3-[4-[6-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 KR 2002071576 A 20020913 KR 2001-11691 20010307
 CA 2411859 AA 20011213 CA 2001-2411859 20010518
 AU 2001058897 A5 20011217 AU 2001-58897 20010518
 EP 1289984 A1 20030312 EP 2001-932368 20010518
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 BR 2001011280 A 20030610 BR 2001-11280 20010518
 NZ 522990 A 20030829 NZ 2001-522990 20010518
 JP 2003535860 T2 20031202 JP 2002-501891 20010518
 US 2003166620 A1 20030904 US 2002-296896 20021127
 US 6689779 B2 20040210
 PRAI KR 2000-30895 A 20000605
 KR 2000-30896 A 20000605
 KR 2000-56035 A 20000923
 KR 2001-11691 A 20010307
 WO 2001-KR821 W 20010518
 OS CASREACT 136:37590; MARPAT 136:37590
 IT 380382-03-6P 380382-09-2P 380382-18-3P
 380382-50-3P 380382-51-4P 380382-58-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of (pyrimidinyl- or pyridinylphenyl)(acetylaminom
 ethyl)oxazolidinones as antibacterial agents)
 RN 380382-03-6 CAPLUS
 CN Carbamic acid, [2-[[[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-
 oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]amino]-2-oxoethyl]-,
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 380382-09-2 CAPLUS
 CN Acetamide, N-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-
 fluorophenyl]-2-pyridinyl]-2-[(methylsulfonyl)oxy]- (9CI) (CA INDEX NAME)

11/539,486


Absolute stereochemistry.



RN 380382-18-3 CAPLUS

CN Carbamic acid, [(1S)-2-[[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380382-50-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-(6-cyano-3-pyridinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 380382-51-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-[(hydroxyamino)iminomethyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380382-58-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-(4-amino-1-piperidinyl)-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 380381-12-4P 380381-16-8P 380381-24-8P
 380381-47-5P 380381-51-1P 380381-52-2P
 380382-01-4P 380382-04-7P 380382-06-9P
 380382-12-7P 380382-25-2P 380382-41-2P
 380382-54-7P 380382-59-2P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of (pyrimidinyl- or pyridinylphenyl)(acetylaminomethyl)oxazolidinones as antibacterial agents)

RN 380381-12-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-(6-amino-3-pyridinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 380381-16-8 CAPLUS

CN Acetamide, N-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-2-hydroxy- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-24-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-[4-(triphenylmethyl)-1-piperazinyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 380381-47-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1-piperazinyl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.





● x HCl

RN 380381-51-1 CAPLUS

CN Acetamide, N-[[[5S)-3-[3-fluoro-4-[6-[4-(hydroxyacetyl)-1-piperazinyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-52-2 CAPLUS

CN Glycine, N,N-dimethyl-, 2-[4-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380382-01-4 CAPLUS

CN Acetamide, N-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-2-amino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

11/539,486




RN 380382-04-7 CAPLUS


CN Acetamide, N-[[(5S)-3-[4-[6-(4-cyano-1-piperazinyl)-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 380382-06-9 CAPLUS


CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-(4-oxo-1-piperidinyl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A



RN 380382-12-7 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-[4-(hydroxyimino)-1-piperidinyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380382-25-2 CAPLUS


CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(4-hydroxy-1-piperidinyl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 380382-41-2 CAPLUS
 CN Acetamide, N-[[(5S)-3-[4-[6-(2,5-dihydro-1H-pyrrol-1-yl)-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380382-54-7 CAPLUS
 CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-[5-(trichloromethyl)-1,2,4-oxadiazol-

11/539,486

3-yl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 380382-59-2 CAPLUS

CN Acetamide, N-[1-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-4-piperidinyl]-2-(acetyloxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






IT 380381-13-5P 380381-14-6P 380381-15-7P
 380381-17-9P 380381-19-1P 380381-20-4P
 380381-21-5P 380381-22-6P 380381-25-9P
 380381-34-0P 380381-35-1P 380381-37-3P
 380381-38-4P 380381-39-5P 380381-40-8P
 380381-48-6P 380381-50-0P 380381-53-3P
 380381-54-4P 380381-55-5P 380381-56-6P
 380381-57-7P 380381-58-8P 380381-68-0P
 380381-69-1P 380381-70-4P 380381-71-5P
 380381-72-6P 380381-73-7P 380381-74-8P
 380381-75-9P 380381-76-0P 380381-77-1P
 380381-78-2P 380381-79-3P 380381-80-6P
 380381-81-7P 380381-82-8P 380381-83-9P
 380381-84-0P 380381-85-1P 380381-86-2P
 380381-87-3P 380381-88-4P 380381-89-5P
 380381-90-8P 380381-91-9P 380381-95-3P
 380381-96-4P 380381-97-5P 380381-98-6P
 380381-99-7P 380382-05-8P 380382-08-1P
 380382-10-5P 380382-11-6P 380382-13-8P
 380382-14-9P 380382-15-0P 380382-16-1P
 380382-19-4P 380382-20-7P 380382-22-9P
 380382-23-0P 380382-26-3P 380382-28-5P
 380382-30-9P 380382-32-1P 380382-34-3P
 380382-35-4P 380382-36-5P 380382-37-6P
 380382-38-7P 380382-39-8P 380382-40-1P
 380382-42-3P 380382-43-4P 380382-44-5P
 380382-45-6P 380382-46-7P 380382-47-8P
 380382-48-9P 380382-49-0P 380382-52-5P
 380382-53-6P 380382-55-8P 380382-56-9P
 380382-57-0P 380382-60-5P 380382-61-6P
 380413-65-0P, (S)-[N-3-[4-(2-Hydroxyacetylaminopyridin-5-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methylacetamide compound with hydroxypropyl methyl cellulose
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of (pyrimidinyl- or pyridinylphenyl)(acetylaminomethyl)oxazolidinones as antibacterial agents)
 RN 380381-13-5 CAPLUS
 CN 3-Pyridinecarboxylic acid, 5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 380381-14-6 CAPLUS

CN Acetamide, N-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380381-15-7 CAPLUS

CN Acetamide, N-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-2-(acetyloxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 380381-17-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1H-imidazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380381-19-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(4-morpholinyl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 380381-20-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-[(triphenylmethyl)amino]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380381-21-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-(6-methoxy-3-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 380381-22-6 CAPLUS

CN Acetamide, N-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380381-25-9 CAPLUS

CN Acetamide, N-[[5-[[4-[(6-azido-3-pyridinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 380381-34-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(methylamino)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380381-35-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-(dimethylamino)-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 380381-37-3 CAPLUS

CN Acetamide, N-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-2-hydroxy-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380381-38-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-(acetyloxy)-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 380381-39-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(methoxymethoxy)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 380381-40-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-[(methylsulfonyl)oxy]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 380381-48-6 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-[6-[4-[(acetyloxy)acetyl]-1-piperazinyl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 380381-50-0 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-[4-[(phenylmethoxy)acetyl]-1-piperazinyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-53-3 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-[6-[4-(chloroacetyl)-1-piperazinyl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-54-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-(4-acetyl-1-piperazinyl)-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-55-5 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-[4-(methoxyacetyl)-1-piperazinyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-56-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-[4-(4-morpholinylacetyl)-1-piperazinyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-57-7 CAPLUS

CN Glycine, N-[2-[4-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-1-piperazinyl]-2-oxoethyl]-, methyl ester
(9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-58-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-68-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-[4-[(methanesulfonyl)oxy]acetyl]-1-piperazinyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-69-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-[4-(1-oxo-2-propenyl)-1-piperazinyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-70-4 CAPLUS

CN 1-Piperazineacetic acid, 4-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]- α -oxo-, ethyl ester (9CI)
(CA INDEX NAME)



Absolute stereochemistry.



RN 380381-71-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-[4-(3-pyridinylcarbonyl)-1-piperazinyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-72-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-[4-(2,2-dimethyl-1-oxopropyl)-1-piperazinyl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-73-7 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-[6-[4-(3,3-dimethyl-1-oxobutyl)-1-piperazinyl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-74-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-[4-[(3-pyridinylmethoxy)acetyl]-1-piperazinyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-75-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-[4-[(2,5-dimethoxyphenyl)acetyl]-1-piperazinyl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-(9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-76-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-[4-(3-methyl-1-oxo-2-butenyl)-1-piperazinyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-77-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-[4-(2,6-dimethoxybenzoyl)-1-piperazinyl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-78-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-[4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-79-3 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-[4-[4-(trifluoromethyl)benzoyl]-1-piperazinyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-80-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-[4-(phenylacetyl)-1-piperazinyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 380381-81-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-[4-(1-oxo-2-butenyl)-1-piperazinyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Double bond geometry unknown.



RN 380381-82-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-[4-(trifluoroacetyl)-1-piperazinyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-83-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-[4-(1-oxopentyl)-1-piperazinyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-84-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-, phenyl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-85-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-86-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-, 1-chloroethyl ester (9CI)
(CA INDEX NAME)



Absolute stereochemistry.



RN 380381-87-3 CAPLUS

1-Piperazinecarboxylic acid, 4-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-, (4-nitrophenyl)methyl ester
(9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-88-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380381-89-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

11/539,486





RN 380381-90-8 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-[4-(2-pyrimidinyl)-1-piperazinyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 380381-91-9 CAPLUS

CN 1-Piperazineacetic acid, 4-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




11/539,486

RN 380381-95-3 CAPLUS


CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-[4-(2-hydroxyethyl)-1-piperazinyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A



RN 380381-96-4 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-[6-[4-[2-(acetyloxy)ethyl]-1-piperazinyl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-97-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380381-98-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-[4-[2-[(methylsulfonyl)oxy]ethyl]-1-piperazinyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 380381-99-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-[4-(hydroxymethyl)-1H-imidazol-1-yl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380382-05-8 CAPLUS

11/539,486


CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-[4-[(hydroxyamino)iminomethyl]-1-piperazinyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 380382-08-1 CAPLUS

CN Acetamide, N-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-2-azido- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

11/539,486





RN 380382-10-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(hexahydro-5-oxo-1H-1,4-diazepin-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 380382-11-6 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-[6-[[(dimethylamino)methylene]amino]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.
Double bond geometry unknown.



RN 380382-13-8 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-[4-[[(methylsulfonyl)oxy]imino]-1-piperidinyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380382-14-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-[4-(methylimino)-1-piperidinyl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 380382-15-0 CAPLUS

CN Hydrazinecarboxylic acid, 2-[1-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-4-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380382-16-1 CAPLUS

CN Propanamide, N-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-2-amino-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 380382-19-4 CAPLUS

CN Acetamide, 2-(acetylamino)-N-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380382-20-7 CAPLUS

CN Acetamide, N-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 380382-22-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380382-23-0 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-(1H-1,2,4-triazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 380382-26-3 CAPLUS

CN Acetamide, N-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-2-hydroxy-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380382-28-5 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-(4-methyl-1H-imidazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 380382-30-9 CAPLUS

CN Propanamide, N-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 380382-32-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-(3-amino-1H-1,2,4-triazol-1-yl)-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2-hydroxy-3-methylbutanamide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 380382-34-3 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 1-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 380382-35-4 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-(1H-tetrazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380382-36-5 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-(5-methyl-1,3,4-oxadiazol-2-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 380382-37-6 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-(5-methyl-1,2,4-oxadiazol-3-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 380382-38-7 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380382-39-8 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-

11/539,486

pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 380382-40-1 CAPLUS

CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-, ethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 380382-42-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(2-oxo-3-oxazolidinyl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




11/539,486

RN 380382-43-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(5-oxazolyl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 380382-44-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1,2,4-oxadiazol-3-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 380382-45-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1H-1,2,3-triazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




11/539,486

RN 380382-46-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-(1,5-dihydro-1-methyl-5-oxo-4H-1,2,4-triazol-4-yl)-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 380382-47-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(2-oxo-1-imidazolidinyl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 380382-48-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-(1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl)-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




11/539,486

RN 380382-49-0 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-[5-(hydroxymethyl)-1,2,4-oxadiazol-3-yl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 380382-52-5 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-(1H-tetrazol-5-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380382-53-6 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-[5-(methoxymethyl)-1,2,4-oxadiazol-3-yl]-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 380382-55-8 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-[6-[5-(dimethylamino)-1,2,4-oxadiazol-3-yl]-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 380382-56-9 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-[6-(5-amino-1,2,4-oxadiazol-3-yl)-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380382-57-0 CAPLUS

CN Acetamide, N-[1-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)


11/539,486

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A



RN 380382-60-5 CAPLUS


CN Acetamide, N-[1-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-4-piperidinyl]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 380382-61-6 CAPLUS
 CN Acetamide, N-[[(5S)-3-[4-[6-(3,4-dihydroxy-1-pyrrolidinyl)-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



11/539,486

RN 380413-65-0 CAPLUS


CN Cellulose, 2-hydroxypropyl methyl ether, compd. with N-[5-[4-[(5S)-5-
[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-2-
hydroxyacetamide (9CI) (CA INDEX NAME)

CM 1

CRN 380381-16-8

CMF C19 H19 F N4 O5

Absolute stereochemistry.



CM 2

CRN 9004-65-3

CMF C3 H8 O2 . x C H4 O . x Unspecified

CM 3

CRN 9004-34-6

CMF Unspecified

CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 4

CRN 67-56-1


CMF C H4 O

H₃C-OH

CM 5

11/539,486

CRN 57-55-6
CMF C3 H8 O2



IT 380381-49-7 380382-07-0 380382-27-4
380382-31-0


RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of (pyrimidinyl- or pyridinylphenyl)(acetylaminomethyl)oxazolidinones as antibacterial agents)

RN 380381-49-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[6-(1-piperazinyl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

RN 380382-07-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[6-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 380382-27-4 CAPLUS

CN Acetamide, N-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-2-(acetyloxy)-N-methyl- (SCI) (CA INDEX NAME)


Absolute stereochemistry.



RN 380382-31-0 CAPLUS

CN Propanamide, N-[5-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-2-pyridinyl]-2-(acetyloxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 38 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:460427 CAPLUS

DN 131:87754

TI Preparation of phenyl pyridinium oxazolidinone cepheims and their
antibacterial activity

IN Yoon, Yeo Hong; Lee, Koun Ho; Song, Seok Bum; Whang, Ho Sung; Lee, Kwang
Hyuk; Kim, Je Hak; Kim, Dal Hyun; Kim, Young Gi; Kang, Jin Ah; Lee, Youn
Ha

PA Cheil Jedang Corporation, S. Korea

SO PCT Int. Appl., 50 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9933839	A1	19990708	WO 1998-KR463	19981224
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	ZA 9811851	A	19990714	ZA 1998-11851	19981223
	AU 9916940	A1	19990719	AU 1999-16940	19981224
PRAI	KR 1997-73893	A	19971226		
	KR 1998-50525	A	19981120		
	WO 1998-KR463	W	19981224		
IT	229647-37-4P 229647-38-5P 229647-45-4P 229647-57-8P				

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);


11/539,486

BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylpyridinium oxazolidinone cepheams and their
antibacterial activity)

RN 229647-37-4 CAPLUS

CN Pyridinium, 3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-[[(6R,7R)-7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 229647-38-5 CAPLUS

CN Pyridinium, 3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-[[(6R,7R)-7-[[(2Z)-(2-amino-4-thiazolyl) [(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




PAGE 1-A

11/539,486


CN Pyridinium, 3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-[[[(6R,7R)-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 229647-62-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenylpyridinium oxazolidinone cepheems and their antibacterial activity)
RN 229647-62-5 CAPLUS
CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-(3-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 39 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:441160 CAPLUS

11/539,486

DN 131:208637
TI Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors
AU Matassova, N. B.; Rodnina, M. V.; Endermann, R.; Kroll, H.-P.; Pleiss, U.; Wild, H.; Wintermeyer, W.
CS Institute of Molecular Biology, University of Witten/Herdecke, Witten, 58448, Germany
SO RNA (1999), 5(7), 939-946
CODEN: RNARFU; ISSN: 1355-8382
PB Cambridge University Press
DT Journal
LA English
IT 128311-89-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rRNA as target for antibacterial oxazolidinone translational inhibitors)
RN 128311-89-7 CAPLUS
CN Acetamide, N-[[[(5S)-2-oxo-3-[4-(3-pyridinyl)phenyl]-5-oxazolidinyl)methyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 40 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:77555 CAPLUS
DN 130:139335
TI Preparation of tricyclically substituted oxazolidinones as bactericides
IN Bartel, Stephan; Guarnieri, Walter; Riedl, Bernd; Habich, Dieter; Stolle, Andreas; Ruppelt, Martin; Raddatz, Siegfried; Rosentreter, Ulrich; Wild, Hanno; Endermann, Rainer; Kroll, Hein-peter
PA Bayer Aktiengesellschaft, Germany; et al.
SO PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9903846	A1	19990128	WO 1998-EP4252	19980708

11/539,486

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

DE 19730847 A1 19990128 DE 1997-19730847 19970718
AU 9884417 A1 19990210 AU 1998-84417 19980708
ZA 9806360 A 19990127 ZA 1998-6360 19980717
PRAI DE 1997-19730847 A 19970718
WO 1998-EP4252 W 19980708
OS MARPAT 130:139335
IT 220059-87-0P 220059-88-1P 220059-89-2P
220059-91-6P 220059-92-7P 220059-93-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of tricyclically substituted oxazolidinones as bactericides)
RN 220059-87-0 CAPLUS
CN Acetamide, N-[[[(5S)-3-[4-(2-fluoro-3-pyridinyl)-3-methoxyphenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220059-88-1 CAPLUS
CN Acetamide, N-[[[(5S)-3-[4-(4-chloro-3-pyridinyl)-3-methoxyphenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 220059-89-2 CAPLUS

CN Carbamic acid, [[[5S)-3-[4-(4-chloro-3-pyridinyl)-3-methoxyphenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220059-91-6 CAPLUS

CN Acetamide, N-[[[5S)-3-[4-(2-fluoro-3-pyridinyl)-3-hydroxyphenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/539,486



RN 220059-92-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-(4-chloro-3-pyridinyl)-3-hydroxyphenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220059-93-8 CAPLUS

CN Carbamic acid, [[[(5S)-3-[4-(4-chloro-3-pyridinyl)-3-hydroxyphenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 41 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:659781 CAPLUS
DN 125:300987
TI Substituted aryl- and heteroarylphenyloxazolidinones
IN Barbachyn, Michael R.; Brickner, Steven J.
PA Upjohn Co., USA
SO U.S., 19 pp., Cont.-in-part of U.S. Ser. No. 831,213, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5565571	A	19961015	US 1994-233903	19940428
	JP 07500603	T2	19950119	JP 1993-508405	19921005
	JP 3176626	B2	20010618		
	AT 146783	E	19970115	AT 1992-921324	19921005
	US 5654428	A	19970805	US 1995-466956	19950606
	US 5654435	A	19970805	US 1995-470522	19950606
	US 5756732	A	19980526	US 1995-466958	19950606
	US 5801246	A	19980901	US 1995-466955	19950606
	US 5929248	A	19990727	US 1997-842282	19970423
PRAI	US 1991-786107	B2	19911101		
	US 1992-831213	B2	19920207		
	WO 1992-US8267	A1	19921005		
	US 1994-233903	A3	19940428		
	US 1995-466955	A3	19950606		

OS MARPAT 125:300987

IT 149523-78-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of heteroaryl- and arylphenyloxazolidinones as bactericides and
tuberculostatics)

RN 149523-78-4 CAPLUS

CN Acetamide, N-[[3-[3,5-difluoro-4-(3-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


11/539,486



IT 149997-01-3P 183124-51-8P 183124-53-0P
183124-55-2P 183124-57-4P 183124-73-4P
183124-76-7P 183124-78-9P 183124-80-3P
183124-82-5P 183124-96-1P 183125-02-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroaryl- and arylphenyloxazolidinones as bactericides and tuberculostatics)
RN 149997-01-3 CAPLUS
CN Acetamide, N-[[3-[3,5-difluoro-4-(3-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 149523-78-4
CMF C17 H15 F2 N3 O3



CM 2


CRN 75-75-2
CMF C H4 O3 S

11/539,486




RN 183124-51-8 CAPLUS

CN Acetamide, N-[[3-[3-fluoro-4-(3-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 183124-53-0 CAPLUS


CN Acetamide, N-[[3-[3-chloro-4-(3-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 183124-55-2 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-(3-pyridinyl)-3-(trifluoromethyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


11/539,486



RN 183124-57-4 CAPLUS
CN Acetamide, N-[[3-[3-methoxy-4-(3-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 183124-73-4 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-(3-quinolinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 183124-76-7 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-(4-isoquinolinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


11/539,486



RN 183124-78-9 CAPLUS
CN Acetamide, N-[[3-[3,5-dichloro-4-(3-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 183124-80-3 CAPLUS
CN Acetamide, N-[[2-oxo-3-[4-(3-pyridinyl)-3,5-bis(trifluoromethyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 183124-82-5 CAPLUS
CN Acetamide, N-[[3-[3,5-dimethoxy-4-(3-pyridinyl)phenyl]-2-oxo-5-


11/539,486

oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 183124-96-1 CAPLUS

CN Acetamide, N-[[3-[3,5-difluoro-4-(3-quinoliny)phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 183125-02-2 CAPLUS

CN Acetamide, N-[[3-[3,5-difluoro-4-(4-isoquinoliny)phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 42 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN


AN 1995:714324 CAPLUS

DN 123:143700

TI Regioselective Metalation of Fluoroanilines. An Application to the Synthesis of Fluorinated Oxazolidinone Antibacterial Agents

11/539,486

AU Grega, Kevin C.; Barbachyn, Michael R.; Brickner, Steven J.; Mizzsak, Stephen A.
CS Upjohn Laboratories, Upjohn Company, Kalamazoo, MI, 49001, USA
SO Journal of Organic Chemistry (1995), 60(16), 5255-61
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
IT 149523-78-4P, Acetamide, N-[[3-[3,5-difluoro-4-(3-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl], (\pm)
RL: SPN (Synthetic preparation); PREP (Preparation)
(regioselective metalation of fluoroaniline and preparation of fluorooxazolidines)
RN 149523-78-4 CAPLUS
CN Acetamide, N-[[3-[3,5-difluoro-4-(3-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 43 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1994:298621 CAPLUS
DN 120:298621
TI [[(Aminomethyl)oxo]oxazolidinyl]arylbenzene antibacterial agents
IN Carlson, Randall K.; Park, Chung Ho; Gregory, Walter A.
PA Du Pont Merck Pharmaceutical Co., USA
SO U.S., 28 pp.
CODEN: USXXAM
DT Patent
LA English
FAN..CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 5254577	A	19931019	US 1991-811400	19911220
PRAI	US 1991-811400		19911220		
OS	MARPAT 120:298621				
IT	128311-89-7P 128311-90-0P 128311-91-1P				
RL:	SPN (Synthetic preparation); PREP (Preparation) (preparation and antibiotic activity)				
RN	128311-89-7 CAPLUS				
CN	Acetamide, N-[[3-[3,5-difluoro-4-(3-pyridinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.


11/539,486



RN 128311-90-0 CAPLUS

CN Acetamide, N-[[3-[4-(1-oxido-3-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 128311-91-1 CAPLUS

CN Acetamide, N-[[3-[4-(4-isoquinolinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 44 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1993:560265 CAPLUS

DN 119:160265

TI Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents

IN Barbachyn, Michael Robert; Brickner, Steven Joseph

PA Upjohn Co., USA

SO PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9309103	A1	19930513	WO 1992-US8267	19921005
	W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	AU 9226898	A1	19930607	AU 1992-26898	19921005
	AU 667198	B2	19960314		
	EP 610265	A1	19940817	EP 1992-921324	19921005
	EP 610265	B1	19961227		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
	JP 07500603	T2	19950119	JP 1993-508405	19921005
	JP 3176626	B2	20010618		
	AT 146783	E	19970115	AT 1992-921324	19921005
	CA 2119556	C	20040706	CA 1992-2119556	19921005
	US 5929248	A	19990727	US 1997-842282	19970423
PRAI	US 1991-786107	A2	19911101		
	US 1992-831213	A2	19920207		
	WO 1992-US8267	A	19921005		
	US 1994-233903	A3	19940428		
	US 1995-466955	A3	19950606		
OS	MARPAT 119:160265				
IT	149523-78-4P		149997-01-3P	183124-51-8P	
	183124-53-0P		183124-55-2P	183124-57-4P	
	183124-73-4P		183124-76-7P	183124-78-9P	
	183124-80-3P		183124-82-5P	183124-96-1P	
	183125-02-2P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological				

11/539,486

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antibacterial)

RN 149523-78-4 CAPLUS

CN Acetamide, N-[[3-[3,5-difluoro-4-(3-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 149997-01-3 CAPLUS

CN Acetamide, N-[[3-[3,5-difluoro-4-(3-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 149523-78-4

CMF C17 H15 F2 N3 O3




CM 2


CRN 75-75-2

CMF C H4 O3 S


11/539,486



RN 183124-51-8 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-(3-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 183124-53-0 CAPLUS
CN Acetamide, N-[[3-[3-chloro-4-(3-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 183124-55-2 CAPLUS
CN Acetamide, N-[[2-oxo-3-[4-(3-pyridinyl)-3-(trifluoromethyl)phenyl]-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

11/539,486




RN 183124-57-4 CAPLUS

CN Acetamide, N-[[3-[3-methoxy-4-(3-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 183124-73-4 CAPLUS


CN Acetamide, N-[[3-[3-fluoro-4-(3-quinolinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 183124-76-7 CAPLUS


CN Acetamide, N-[[3-[3-fluoro-4-(4-isoquinolinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

11/539,486




RN 183124-78-9 CAPLUS

CN Acetamide, N-[[3-[3,5-dichloro-4-(3-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 183124-80-3 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-(3-pyridinyl)-3,5-bis(trifluoromethyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 183124-82-5 CAPLUS

CN Acetamide, N-[[3-[3,5-dimethoxy-4-(3-pyridinyl)phenyl]-2-oxo-5-


11/539,486

oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 183124-96-1 CAPLUS

CN Acetamide, N-[[3-[3,5-difluoro-4-(3-quinolinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 183125-02-2 CAPLUS

CN Acetamide, N-[[3-[3,5-difluoro-4-(4-isoquinolinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 45 OF 45 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1990:572003 CAPLUS

DN 113:172003

TI 5-(Aminomethyl)-3-(4-arylphenyl)oxazolidin-2-one derivatives useful as antibacterial agents

11/539,486

IN Carlson, Randall Kent; Gregory, Walter Adelman; Park, Chung Ho
 PA du Pont de Nemours, E. I., and Co., USA
 SO Eur. Pat. Appl., 55 pp.
 CODEN: EPXXDW

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 352781	A2	19900131	EP 1989-113837	19890727
	EP 352781	A3	19900711		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 4948801	A	19900814	US 1988-225809	19880729
	DK 8903743	A	19900130	DK 1989-3743	19890728
	FI 8903618	A	19900130	FI 1989-3618	19890728
	NO 8903076	A	19900130	NO 1989-3076	19890728
	JP 02124877	A2	19900514	JP 1989-194442	19890728
	JP 2899319	B2	19990602		
	ZA 8905778	A	19910327	ZA 1989-5778	19890728
	HU 58062	A2	19920128	HU 1989-3901	19890728
	CA 1337526	A1	19951107	CA 1989-607006	19890728
	AU 8939115	A1	19900201	AU 1989-39115	19890731
	AU 622465	B2	19920409		
	US 5043443	A	19910827	US 1990-558131	19900724
	US 5130316	A	19920714	US 1990-558129	19900725
	US 5254577	A	19931019	US 1992-929452	19920814
PRAI	US 1988-225809	A	19880729		
	US 1990-558126	B3	19900724		

OS MARPAT 113:172003


IT 128311-89-7P 128311-90-0P 128311-91-1P
 128312-08-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as antibacterial)

RN 128311-89-7 CAPLUS

CN Acetamide, N-[[(5S)-2-oxo-3-[4-(3-pyridinyl)phenyl]-5-oxazolidinyl)methyl]-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 128311-90-0 CAPLUS

CN Acetamide, N-[[3-[4-(1-oxido-3-pyridinyl)phenyl]-2-oxo-5-

11/539,486

oxazolidinyl)methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 128311-91-1 CAPLUS

CN Acetamide, N-[[3-[4-(4-isoquinoliny)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 128312-08-3 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-(3-pyridinyl)phenyl]-5-oxazolidinyl]methyl]-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

11/539,486



● HCl

=> log y

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE
ENTRY

158.41

TOTAL
SESSION

326.00

STN INTERNATIONAL LOGOFF AT 14:36:42 ON 14 AUG 2006